75 related articles for article (PubMed ID: 16720057)
1. Regression of cardiac hypertrophy in type 2 diabetes with hypertension by candesartan.
Iwashima Y; Okada M; Haneda M; Yoshida T
Diabetes Res Clin Pract; 2006 Oct; 74(1):8-14. PubMed ID: 16720057
[TBL] [Abstract][Full Text] [Related]
2. Losartan and amlodipine on myocardial structure and function: a prospective, randomized, clinical trial.
Fogari R; Mugellini A; Destro M; Corradi L; Lazzari P; Zoppi A; Preti P; Derosa G
Diabet Med; 2012 Jan; 29(1):24-31. PubMed ID: 21781149
[TBL] [Abstract][Full Text] [Related]
3. ARB candesartan and CCB amlodipine in hypertensive patients: the CASE-J trial.
Ogihara T; Fujimoto A; Nakao K; Saruta T;
Expert Rev Cardiovasc Ther; 2008 Oct; 6(9):1195-201. PubMed ID: 18939907
[TBL] [Abstract][Full Text] [Related]
4. Indapamide SR versus candesartan and amlodipine in hypertension: the X-CELLENT Study.
London G; Schmieder R; Calvo C; Asmar R
Am J Hypertens; 2006 Jan; 19(1):113-21. PubMed ID: 16461202
[TBL] [Abstract][Full Text] [Related]
5. Effects of candesartan versus amlodipine on home-measured blood pressure, QT dispersion and left ventricular hypertrophy in high-risk hypertensive patients.
Matsuno Y; Minatoguchi S; Fujiwara H;
Blood Press Suppl; 2011 Apr; 1():12-9. PubMed ID: 21247247
[TBL] [Abstract][Full Text] [Related]
6. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
[TBL] [Abstract][Full Text] [Related]
7. Long-term effects of candesartan and amlodipine on cardiovascular morbidity and mortality in Japanese high-risk hypertensive patients: the Candesartan Antihypertensive Survival Evaluation in Japan Extension Study (CASE-J Ex).
Ogihara T; Ueshima K; Nakao K; Fukiyama K; Oba K; Yasuno S; Fujimoto A; Sato T; Matsuoka H; Saruta T;
Hypertens Res; 2011 Dec; 34(12):1295-301. PubMed ID: 21833000
[TBL] [Abstract][Full Text] [Related]
8. Role of diabetes and obesity in outcomes of the candesartan antihypertensive survival evaluation in Japan (CASE-J) trial.
Nakao K; Hirata M; Oba K; Yasuno S; Ueshima K; Fujimoto A; Ogihara T; Saruta T;
Hypertens Res; 2010 Jun; 33(6):600-6. PubMed ID: 20379187
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study.
Rakugi H; Ogihara T; Miyata Y; Sasai K; Totsuka N
Clin Ther; 2012 Apr; 34(4):838-48. PubMed ID: 22440192
[TBL] [Abstract][Full Text] [Related]
10. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study).
Yamaguchi J; Hagiwara N; Ogawa H; Koyanagi R; Kasanuki H; Takagi A; Mori F; Nagashima M; Yagi M;
Am J Cardiol; 2010 Sep; 106(6):819-24. PubMed ID: 20816122
[TBL] [Abstract][Full Text] [Related]
11. Effects of candesartan and amlodipine on cardiovascular events in hypertensive patients with chronic kidney disease: subanalysis of the CASE-J Study.
Saruta T; Hayashi K; Ogihara T; Nakao K; Fukui T; Fukiyama K;
Hypertens Res; 2009 Jun; 32(6):505-12. PubMed ID: 19390535
[TBL] [Abstract][Full Text] [Related]
12. [Effect of the treatment with amlodipine on left ventricular hypertrophy in hypertensive patients].
Oliván J; Moreno R; Hoyos M; Ramos E; Rodríguez A; Pizarro JL; Justo E; Pérez Cano R
An Med Interna; 1996 Nov; 13(11):531-6. PubMed ID: 9019211
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of candesartan and amlodipine on cardiovascular mortality and morbidity in Japanese high-risk hypertensive patients: rationale, design, and characteristics of candesartan antihypertensive survival evaluation in Japan extension (CASE-J Ex).
Ueshima K; Oba K; Yasuno S; Fujimoto A; Sato T; Fukiyama K; Azuma J; Ogihara T; Saruta T; Nakao K;
Contemp Clin Trials; 2009 Jan; 30(1):97-101. PubMed ID: 18824134
[TBL] [Abstract][Full Text] [Related]
14. Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension.
Spoelstra-de Man AM; van Ittersum FJ; Schram MT; Kamp O; van Dijk RA; Ijzerman RG; Twisk JW; Brouwer CB; Stehouwer CD
J Hum Hypertens; 2006 Aug; 20(8):599-611. PubMed ID: 16673014
[TBL] [Abstract][Full Text] [Related]
15. Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.
Grandi AM; Solbiati F; Laurita E; Maresca AM; Nicolini E; Marchesi C; Gianni M; Guasti L; Venco A
Am J Hypertens; 2008 Feb; 21(2):231-7. PubMed ID: 18174880
[TBL] [Abstract][Full Text] [Related]
16. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial.
Schram MT; van Ittersum FJ; Spoelstra-de Man A; van Dijk RA; Schalkwijk CG; Ijzerman RG; Twisk JW; Stehouwer CD
J Hum Hypertens; 2005 Jun; 19(6):429-37. PubMed ID: 15647778
[TBL] [Abstract][Full Text] [Related]
17. Regression of left ventricular hypertrophy in diabetics by a candesartan-based regimen in clinical practice.
Barrios V; Escobar C; Calderón A; Vegazo O; Fernandez R; Asín E
Diabetes Res Clin Pract; 2007 Sep; 77(3):492-3. PubMed ID: 17306904
[No Abstract] [Full Text] [Related]
18. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
19. [Effects of renin-angiotensin system blockers on left ventricular hypertrophy and biochemical markers of collagen balance in patients with hypertensive hypertrophy].
Ovchinnikov AG; Serbul VM; Ageev FT
Ter Arkh; 2009; 81(5):64-71. PubMed ID: 19537590
[TBL] [Abstract][Full Text] [Related]
20. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease.
Nutahara K; Higashihara E; Horie S; Kamura K; Tsuchiya K; Mochizuki T; Hosoya T; Nakayama T; Yamamoto N; Higaki Y; Shimizu T
Nephron Clin Pract; 2005; 99(1):c18-23. PubMed ID: 15637459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
